Table 3.
Factors associated with prolongation of progression-free survival (PFS) by 30% or greater in later lines of therapy.
| Univariable | Multivariable | ||||
|---|---|---|---|---|---|
| Parameters | Patients with PFS2/PFS1≥1.3 (%)6 | OR (95% CI) | P7 | OR (95% CI) | P7 |
| Evaluable patients1 (N=53) | 24/53=45.3% | --- | --- | --- | --- |
| Age2 | |||||
| < 62 years old (N=24) | 9/24=37.5% | 0.56 (0.19–1.69) | 0.302 | --- | --- |
| ≥ 62 years old (N=29) | 15/29=51.7% | ||||
| Gender | |||||
| Women (N=36) | 15/36=41.7% | 0.64 (0.20–2.03) | 0.443 | --- | --- |
| Men (N=17) | 9/17=52.9% | ||||
| Patients with ≥1 matched therapy administered | |||||
| YES (N=46) | 22/46=47.8% | 2.29 (0.40–13.04) | 0.350 | --- | --- |
| NO (N=7) | 2/7=28.6% | ||||
| Matching Score3 | |||||
| >50% (N=12) | 9/12=75.0% | 5.20 (1.22–22.23) | 0.026 | 8.18 (1.50–44.77) | 0.015 |
| ≤50% (N=41) | 15/41=36.6% | ||||
| Gastrointestinal cancer (includes hepatopancreatobiliary cancer) | |||||
| YES (N=23) | 10/23=43.5% | 0.88 (0.30–2.62) | 0.817 | --- | --- |
| NO (N=30) | 14/30=46.7% | ||||
| Gynecologic cancer | |||||
| YES (N=10) | 3/10=30.0% | 0.45 (0.10–1.97) | 0.289 | 0.20 (0.03–1.42) | 0.108 |
| NO (N=43) | 21/43=48.8% | ||||
| Combination therapy4 | |||||
| YES (N=38) | 18/38=47.4% | 1.35 (0.40–4.54) | 0.628 | --- | --- |
| NO (N=15) | 6/15=40.0% | ||||
| Prior lines of therapy5 | |||||
| ≤2 (N=20) | 7/20=35.0% | 0.51 (0.16–1.59) | 0.245 | 0.48 (0.13–1.73) | 0.262 |
| >2 (N=33) | 17/33=51.5% | ||||
N=53 patients were evaluable for this analysis. Patients were inevaluable mainly because the PFS1 was in the adjuvant/neoadjuvant setting or was a matched therapy.
Age cut-off chosen corresponds to the median age.
The cut-off of 50% for the Matching Score was chosen according to the minimum P-value criteria.19
Combination therapy refers to administrations of molecularly matched multi-drug regimens.
Cut-off chosen was the median line of therapy administered.
PFS2 refers to progression-free survival on the I-PREDICT protocol; PFS1 refers to progression-free survival on the prior unmatched therapy (in a metastatic or an unresectable setting).
P-values by Kaplan-Meier method [two-sided log-rank test (univariable analysis); Cox regression (multivariate analysis)]; variables with P<0.3 in univariable analysis were included in the Cox regression model (multivariable analysis).